Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

View:
Post by lonc17 on Oct 10, 2023 8:50pm

MM Trial

Curious that ONC has not issued a press release:

https://pubmed.ncbi.nlm.nih.gov/37812476/



Comment by lonc17 on Oct 10, 2023 8:55pm
A better link: https://watermark.silverchair.com/ccr-23-0229.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA20wggNpBgkqhkiG9w0BBwagggNaMIIDVgIBADCCA08GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMqp-Sh4WTfbOZbnxdAgEQgIIDIC5awxdOv0xOu-nMbTGIQvLRfMfgRbI17Lc5lUbrBFquVynDH57gd8jWjvND10cM-vcBfiK1IghEdK49T7-QJTBw5y7KuoWSRgDe8G1QNoob4U7kUnysm0WksacPwctQ_dODyC0Se-SnI4w ...more  
Comment by lonc17 on Oct 10, 2023 8:59pm
Among the 11 response-evaluable patients, 1 had a VGPR, 1 had a PR, 2 had a minor response (MR), 4 had stable disease (SD) lasting at least 1 cycle, and 3 had PD after 1 cycle (Table 1)
Comment by canadafan on Oct 11, 2023 6:50am
Onc has a few quiet trails on-the- go, beyond the well discussed PanCan & MBc phase 3 ready. The MM just one of them. Are the results worthy of a N.R. ? regardless, with the very high short holdings, and recent general markets uptick, I see a nice run coming. I have been wrong before ( blah blah blah),  none the less, more up indicators than down. great week all.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities